Epothilone D
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Epothilone D
- Molecular weight
- 491.69
- Structure (SMILES)
- C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1
- (-)-desoxyepothilone b
- 12 13 desoxyepothilone b
- 12 13 desoxyepothilone b cis
- 12,13-desoxyepothilone b
- 12,13-desoxyepothilone b, cis
- desoxyepothilone b
- Desoxyepothilone b
- epothilone d
- epothilone D
- Epothilone d
- Epothilone D
- Epothilone D (KOS-862)
- EPOTHILONE D [MI]
- Epothilone D [WHO-DD]
- epothilone d mi
- epothilone d who dd
- kos 862
- KOS-862
- nsc 703147
- NSC-703147
- r 1492
- R-1492
- r1492
- R1492
- utidelone
And 9 more, listed on the interactive page.
- CAS registry numbers
- 189453-10-9
- ChEMBL ID
- CHEMBL96172
- InChIKey
- XOZIUKBZLSUILX-GIQCAXHBSA-N
- PubChem compound IDs
- 447865
- FDA ingredient codes (UNII)
- T0358E0YUF
- First in class
- No
- Orphan designation
- No
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- P04350
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- P07437
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- P0DPH7
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- P68363
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- P68366
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- P68371
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q13509
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q13885
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q3ZCM7
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q6PEY2
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q71U36
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q9BQE3
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q9BUF5
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q9BVA1
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Protein identifier
- Q9H4B7
Open Targets mechanisms
- Mechanism
- Tubulin stabiliser
- Action type
- STABILISER
- Target
- Tubulin
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition
- Lung Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008903
- Subject identifier
- D008175
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008903
- Highest recorded phase
- 2
- NCT00030173
- NCT00077259
- NCT00080509
- NCT00081107
- NCT00104130
- NCT00337649
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 2
- Polar surface area
- 96.72
- Calculated partition coefficient (ALogP)
- 5.27
- Calculated partition coefficient (XLogP)
- 5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 2
- Heavy atoms
- 34
- Molecular formula
- C27H41NO5S
- Monoisotopic mass
- 491.27054458
- Natural product
- Yes
- Recorded assays
- 156
- Active assays
- 95
- Confirmatory
- Screening
- Tubulin Modulators
Related records
Trials (48)
- A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
- A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers
- A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
- A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
- A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
- A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC
- A Study in Patients With Advanced Breast Cancer
- A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer
- A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure
- A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors
- Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
- Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
- Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
- Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
- Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
- Effectiveness of KOS-862 in the Treatment of Lung Cancer
- Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer
- Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer
In development for (5)
- Breast cancer Phase 1
- Colorectal cancer Phase 2
- Lung cancer Phase 2
- Neoplasm Phase 1
- Prostate cancer Phase 2
Targets (15)
- TUBA1A Tubulin stabiliser
- TUBA1B Tubulin stabiliser
- TUBA1C Tubulin stabiliser
- TUBA3C Tubulin stabiliser
- TUBA3E Tubulin stabiliser
- TUBA4A Tubulin stabiliser
- TUBB Tubulin stabiliser
- TUBB1 Tubulin stabiliser
- TUBB2A Tubulin stabiliser
- TUBB2B Tubulin stabiliser
- TUBB3 Tubulin stabiliser
- TUBB4A Tubulin stabiliser
- TUBB4B Tubulin stabiliser
- TUBB6 Tubulin stabiliser
- TUBB8 Tubulin stabiliser